Press room

•This award is recognition of the hard work and dedication of Silvia Gold, President of the Mundo Sano Foundation, in changing the course of Chagas disease.

•Mundo Sano is currently running the campaign Not a Single Baby with Chagas, to ensure that all babies and women of reproductive age have access to diagnosis and treatment.

•Chagas disease affects 8 million people worldwide. In Spain, there are estimated to be between 50,000 and 100,000 Chagas sufferers. Globally, almost 9,000 babies are born with Chagas disease every year.

Exeltis recently presented its manufacturing plant in Guatemala, located in Mixco’s zone 2, which formulates medicines for use in the areas of Women’s Health, Central Nervous System and Respiratory and Cardio Metabolic Diseases. The medicines manufactured are available in the domestic market and exported to the rest of Central America, the Dominican Republic, the Caribbean and Belize

Insud Pharma group have once again been rated “very good” in the 2018 edition of the Spanish government’s Profarma Programme, thanks to its industrial activity and commitment to R&D.

• "Not a Single Baby with Chagas" is a reflection of the Foundation’s commitment to ensuring that by 2030 all babies born with Chagas disease can be treated and cured, and that all women of reproductive age have access to diagnosis and treatment.
• Every hour, a baby is born somewhere in the world with Chagas disease. It is estimated that 9,000 babies are born with the disease every year. 
• Chagas disease affects 8 million people worldwide; in Spain alone, at least 50,000 people are infected.

BioDan, a 3D dressing derived from human skin which can be bioprinted and frozen, Brainguard, a wearable system that predicts migraines, and Insulclock, a system which monitors and controls the treatment of diabetes patients are the three startups selected in the second round of the ChemoStart accelerator programme, which seeks to support innovative, disruptive solutions that improve people’s health and wellbeing.

According to Dr. Santiago Palacios, Director of the Palacios Institute for Women’s Health and Medicine, “thromboembolic events associated to combined hormonal contraceptives (CHC) are believed to affect between 8 and 12 women out of every 10,000. For women who do not take contraceptives, the risk falls to 4 out of every 10,000, and for women using progestogen-only pills it has been shown that it actually impacts between 2 and 4 women out of 10,000, an even lower rate than the general population. The risk of a thromboembolic event is therefore three times lower than with CHCs.¹” 

The ChemoStart Programme is an initiative by Insud Pharma, spearheaded by Leandro Sigman, to support innovative healthcare startups

In the second edition of the programme, 12 finalists have been shortlisted to present to a panel of experts at the Pitch Day on Thursday 31 January

The study of the brain and the way it works is becoming increasingly accessible as technology progresses and new tools are developed in the fields of neurology and psychiatry, among other sciences. The second edition of CNS Exeltis Day was organised with a view to pooling the wealth of existing knowledge on the brain and sharing both common and differential elements of neurology and psychiatry.

Two new grants for research into headaches and epilepsy were conferred within the framework of the 70th Annual Meeting of the Spanish Neurology Society (SEN). The research will seek to predict patients’ migraine attacks using markers and reduce the intensity and number of epileptic seizures. These grants not only represent an opportunity to enhance the quality of life of patients and their families, but will also promote research among young neurologists, encouraging doctoral training in the two fields.

Exeltis has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda® (4mg Drospirenone-only pill), the novel oral contraceptive developed by the company. The Prescription Drug User Fee Act (PDUFA) date is expected during the 27 May of 2019.